Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Kura Oncology (KURA) PT Lowered to $32 at H.C. Wainwright
November 24, 2021 10:20 AM ESTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Kura Oncology (NASDAQ: KURA) to $32.00 (from $43.00) while maintaining a Buy rating.
The analyst commented, "This morning, Kura announced the FDA has placed a partial clinical hold on the KOMET-001 Phase 1b study evaluating KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The hold was put in place... More
